Global pharmaceutical company Novo Nordisk has reportedly released positive new diabetes clinical trial data. The results, published in the Lancet, concern the diabetes drug liraglutide.
The new data reported shows that when liraglutide is taken alone it significantly improves and maintains improvements in blood glucose control amongst type 2 diabetes patients.
Liraglutide was also found to be associated with weight loss, lower blood pressure, and lower hypoglycaemia following a year of treatment. The principal study investigator, Alan Garber, reportedly commented:
“Publication of this data in the Lancet means that more physicians will have access to these key results on liraglutide’s efficacy as monotherapy in the treatment of type two diabetes .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…